CPRX News and Press, Catalyst Pharmaceuticals Inc. From 05/07/19

Gainers:  Bridgeline Digital (NASDAQ: BLIN ) +30% . Cohu (NASDAQ: COHU ) +27% . ATA (NASDAQ: ATAI ) +25% . ARCA biopharma (NASDAQ: ABIO ) +24% . SolarEdge Technologies (NASDAQ: SEDG ) +23% . Summit Wireless Technologies (NASDAQ: WISA ) +22% . Itron (NASDAQ: ITRI ) +21% . Sunwor...

Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...

Catalyst Pharmaceuticals (NASDAQ: CPRX )  -39%  after FDA OKs Firdapse competitor. More news on: Catalyst Pharmaceuticals, Inc., Intersect ENT, Inc., TherapeuticsMD, Inc., Stocks on the move, Read more ...

Catalyst Pharmaceuticals (NASDAQ: CPRX ) -42.7% after-hours following the Food and Drug Administration's approval of a competitor to its Firdapse drug that helps patients who suffer from Lambert-Eaton myasthenic syndrome, for which CPRX charges a list price of $375K. More news on: Cata...

CORAL GABLES, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today...

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...

March 26, 2019 Palm Beach, FL – March 26, 2019 – Research for the cure for cancer has become this generation’s version of President John F. Kennedy’s May 25, 1961 proclamation to “… landing a man on the Moon and returning him safely”. ...

(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...

Catalyst Pharmaceuticals ( CPRX +14.7% ) is up on 50% higher volume. Shares have rallied over  50%  since last week when it delivered a corporate overview at Oppenheimer's healthcare event. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move...

The following slide deck was published by Catalyst Pharmaceuticals, Inc. in conjunction with this Read more ...